Misonix (NASDAQ:MSON) was upgraded by analysts at TheStreet from a “d+” rating to a “c” rating in a research report issued on Tuesday, TheStreetRatingsTable reports.

Shares of MSON opened at $19.04 on Tuesday. The firm has a market capitalization of $331.14 million, a price-to-earnings ratio of -13.04 and a beta of 1.48. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.43 and a current ratio of 3.13. Misonix has a one year low of $9.06 and a one year high of $20.71. The stock’s fifty day moving average is $18.80 and its 200-day moving average is $14.57.

Misonix (NASDAQ:MSON) last announced its earnings results on Thursday, February 4th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.22. Misonix had a negative net margin of 35.03% and a negative return on equity of 16.94%. The firm had revenue of $18.26 million during the quarter.

A number of large investors have recently made changes to their positions in MSON. Citigroup Inc. boosted its stake in Misonix by 303.1% during the 4th quarter. Citigroup Inc. now owns 2,330 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 1,752 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Misonix by 12.6% in the fourth quarter. Rhumbline Advisers now owns 13,351 shares of the medical equipment provider’s stock valued at $167,000 after buying an additional 1,495 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in Misonix during the third quarter valued at about $214,000. JPMorgan Chase & Co. grew its holdings in Misonix by 281.6% during the fourth quarter. JPMorgan Chase & Co. now owns 17,094 shares of the medical equipment provider’s stock worth $214,000 after acquiring an additional 12,614 shares during the period. Finally, Mesirow Financial Investment Management Inc. raised its position in Misonix by 7.4% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,835 shares of the medical equipment provider’s stock worth $310,000 after acquiring an additional 1,719 shares in the last quarter. 41.19% of the stock is currently owned by hedge funds and other institutional investors.

Misonix Company Profile

Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.

Featured Story: Return on Equity (ROE)

Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.